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REQUIRED SUMMARY: Almost half of the 1,122 patients who switched to a second anti-TNF 
after primary failure, secondary failure or intolerance to the first anti-TNF achieved remission after 




BACKGROUND: The effectiveness of the switch to another anti-TNF agent is barely 
known. 
AIMS: To analyse the effectiveness and safety of the treatment with a second and a third anti-
TNF drug after intolerance or failure to a previous anti-TNF agent in inflammatory bowel 
disease (IBD) patients.  
METHODS: We included patients diagnosed with IBD from ENEIDA registry who received 
another anti-TNF after intolerance or failure to a prior anti-TNF agent.  
RESULTS: 1,122 patients were included. In the short-term, remission was achieved in 55% 
of them with the second anti-TNF. The incidence of loss of response was 19% per patient-
year with the second anti-TNF. Combination therapy (HR=2.4; 95%CI=1.8-3, P<0.0001) and 
ulcerative colitis vs. Crohn’s disease (HR=1.6; 95%CI=1.1-2.1, P=0.005) were associated 
with a higher probability of loss of response. Fifteen percent of the patients had adverse 
events and 10% had to discontinue the second anti-TNF. Of the 71 patients who received a 
third anti-TNF, 55% achieved remission. The incidence of loss of response was 22% per 
patient-year with a third anti-TNF. Adverse events occurred in 7 patients (11%), but only 1 
stopped the drug. 
CONCLUSION: Approximately half of the patients who received a second anti-TNF 
achieved remission; nevertheless, a significant proportion of them subsequently lost response. 
Combination therapy and type of IBD were associated with loss of response. Remission was 
achieved in almost 50% of patients who received a third anti-TNF; nevertheless, a significant 
proportion of them subsequently lost response.  
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Anti-TNF drugs are certainly effective in patients diagnosed with inflammatory bowel 
disease (IBD). Nevertheless, approximately 30% of IBD patients treated with anti-TNF 
agents are non-responders to the therapy, and a significant proportion of those who respond 
experiences intolerance or loss of response over time1. The use of a second anti-TNF is a 
common practice when a first one has failed2. In this context, a significant number of patients 
will be treated with a second anti-TNF. Nevertheless, the clinical management of patients 
who experiences loss of response to a first anti-TNF agent is done empirically. A recent meta-
analysis found that the efficacy of a second anti-TNF drug in patients diagnosed with Crohn’s 
disease (CD) was clearly dependent on the reason for switching treatment2. On the other hand, 
only few studies have evaluated the efficacy of a second anti-TNF in ulcerative colitis (UC) 
patients, and the remission rates reported are highly variable3-9. Moreover, a significant 
number of patients who have an initial response to a second anti-TNF finally lose the 
response or became intolerant to the drug10. Furthermore, the use of a third anti-TNF agent 
when the second one has failed is not unusual; however, available data are scarce. In the last 
few years, new molecules have been incorporated into the therapeutic armamentarium for 
IBD patients. However, these treatments are not effective in all patients. For this reason, it is 
important to get the most out of anti-TNF drugs. 
The aims of our study were to evaluate the effectiveness and the safety of the sequential use of 
a second and a third anti-TNF agent after intolerance to or failure of a previous anti-TNF drug, to 
identify the predictors of remission with a second anti-TNF, and to investigate which variables are 






The study included patients that have been diagnosed with CD or UC from ENEIDA 
registry who received another anti-TNF after intolerance or intolerance to a prior anti-TNF 
drug in order to achieve clinical remission. ENEIDA is a prospectively maintained registry of 
the Spanish Working Group in Crohn’s disease and Ulcerative Colitis (GETECCU), which 
includes patients with IBD. The database prospectively records clinical characteristics of the 
patients, and the use, effectiveness, and adverse events of immunomodulators and biologic 
therapy. Physicians from IBD centers that are registered in ENEIDA can voluntarily include 
the data of their patients in ENEIDA. At the time of data extraction, the registry contained 
11,866 patients who were exposed to anti-TNF therapy. ENEIDA registry was approved by 
Research Ethic Committees in all participating centers. All co-authors had access to the study 
data and have reviewed and approved the final manuscript. 
Patients were excluded from the study if the anti-TNF agent was initiated for treatment of 
extraintestinal manifestations of IBD or as a preventive therapy of post-operative recurrence 
in CD patients, if the time between the end of the previous anti-TNF and the onset of the 
second or third anti-TNF was longer than 6 months, and if the previous anti-TNF was stopped 
for other reasons than failure or intolerance (e.g. elective decision, pregnancy, etc.). 
 
Data collection 
The data collected included demographic data, age at diagnosis, smoking habit, duration of 
IBD, location, disease extent, disease behavior, perianal disease, extraintestinal 
manifestations, history of abdominal surgery due to IBD, concomitant therapy with 
immunomodulators, type of anti-TNF agent, indications for anti-TNF therapy, reasons for 
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discontinuation of the anti-TNF, response to anti-TNF and the need to dose escalation, and 
the occurrence of adverse events.  
 
Definitions of study variables 
Primary failure: it was considered that the patient had a primary failure if she/he did not 
achieve remission after having received the induction doses of the anti-TNF (non-responders 
and partial-responders). 
Secondary failure: it was considered that a patient had a secondary failure if she/he 
achieved remission with the anti-TNF agent and then lost effectiveness over time. 
Intolerance to treatment: the patient was considered intolerant to the anti-TNF treatment 
if he/she had adverse events that led to withdraw the drug.  
Sequential use of anti-TNF drugs: if the period of time between the end of the first or 
second anti-TNF drug (due to intolerance, primary failure or secondary failure) and the onset 
of the next anti-TNF was less than 6 months. 
Loss of efficacy: if the patient achieved remission with the anti-TNF agent and then had 
symptoms compatible with clinical activity together with radiographic, endoscopic and/or 
biochemical evidence of disease activity that leaded to a dose escalation or to switch to 
another anti-TNF. 
Dose escalation: if the patient was treated with adalimumab (ADA), a reduction in the 
interval of administration was defined as a dose escalation. A decrease in the administration 
interval, an increase in the dose or both were considered dose escalation in patients treated 
with infliximab (IFX) 
Concomitant immunomodulators (IMMs): immunosuppressive treatment was considered 
concomitant with anti-TNF if the patient had been on IMMs (e.g. azathioprine, 
mercaptopurine or methotrexate) after starting the anti-TNF therapy for a period greater or 
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equal than 6 months. 
Smoking: patients were categorized as having smoked or as never having smoked.  
Clinical remission: a Harvey-Bradshaw index score ≤ 4 points was considered remisson 
for luminal CD 11. A partial Mayo score ≤ 2 points was considered remission for UC 
patients12.  
Short-term effectiveness: it was defined as remission at week 12 (after induction doses) 
Long-term effectiveness: it was defined as the proportion of patients that maintained 
clinical remission with the anti-TNF along time.  
 
Statistical analysis 
In the descriptive analysis, we used the mean and standard deviation for quantitative 
variables if they were normally distributed. If they were not, we used the median and 
interquartile range (IQR). The 95% confidence intervals (95% CIs) and the percentage were 
provided for the categorical variables. The t test for independent samples was used to perform 
comparisons between means. The χ2 test and the Fisher exact test were used to compare the 
categorical variables if they were normally distributed. If they were not, the Wilcoxon rank-
sum test was used. A P < 0.05 was considered statistically significant.  
In the case of the second anti-TNF agent, the factors associated with the short-term 
efficacy were studied with multivariate analyses (logistic regression). The variables that were 
statistically significant after performing a univariate analysis were included in the multivariate 
analysis. Moreover, those variables that could be relevant even if they were not statistically 
significant were also included.  
In the patients that achieved remission in the short-term with a second and or third anti-
TNF agent, Kaplan-Meier curves were used to estimate the long-term maintenance of 
remission. Long-rank test was used to evaluate the impact of some variables on long-term 
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remission. In the group of patients that achieved remission with the second anti-TNF therapy, 
predictive factors for loss of efficacy was identified using a Cox regression model. All the 
variables that reached statistical significance in the univariate analysis and those that were 
considered clinically relevant were included in the multivariate analysis. The dependent 
variable was the loss of efficacy to a given anti-TNF.  
 
Ethical considerations 
The study was approved by the respective institutional ethics review boards, and was 





We included 1,122 IBD (CD or UC) patients that switched to a second anti-TNF after 
failing (primary or secondary failure) or were intolerant to a first anti-TNF drug and met the 
inclusion criteria. The main characteristics of the study population are summarized in Table 1.  
The median duration of the first anti-TNF therapy before switching to a second anti-TNF 
was 12 months (IQR 4-26). 
Most of the patients (67%) had received IFX as a first anti-TNF agent. Most of the patients 
(65%) received ADA as a second anti-TNF. Approximately half of the patients (51%) who 
switched to a third anti-TNF received certolizumab.  
Sixty-two percent of the patients received IMMs with the first anti-TNF, 33% of them 
continued this therapy after switching to a second anti-TNF drug, and 23% with the third. The 
reasons for discontinuation of the first anti-TNF were: secondary failure (51%), intolerance 
(27%), and primary failure (non-responders and partial responders, 22%). In a subanalysis, 
the mean time from the IBD diagnosis until the start of the second anti-TNF was shorter in 
patients on combo therapy with the second anti-TNF than in those on anti-TNF monotherapy 
(85 months vs. 102 months, P=0.003). Similarly, the mean duration of disease until the start 
of the first anti-TNF was shorter in patients on combo therapy with the second anti-TNF (68 
months vs. 82 months, P=0.009). 
 
Second anti-TNF: short-term effectiveness  
After the start of the second anti-TNF drug, the median time of follow-up was 14 months 
(IQR 5-32). In the short-term, 45% (500) of the patients achieved remission wit the second 
anti-TNF agent. Patients who switched to a second anti-TNF due to intolerance to the first 
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drug had higher remission rates than those who switched due to secondary failure (52% vs. 
42%, P=0.003) or primary failure (52% vs. 39%, P=0.003). We did not find difference 
between patients who switched due to primary failure vs. secondary failure (39% vs. 42%, 
P=0.5). Remission rate in the short-term was similar in CD patients (46%) in comparison with 
UC patients (41%), P=0.06. Remission rates were similar among the sequences of the anti-
TNF administration: adalimumab-infliximab or infliximab-adalimumab (48% vs. 42%, 
P=0.07). 
In the multivariate analyses (Table 2), combo therapy (OR=0.5, 95% CI=0.4-0.8), 
withdrawal of the first anti-TNF due to a primary failure (vs. intolerance; OR=0.6, 95% 
CI=0.4-0.9) and withdrawal of the first anti-TNF due to secondary failure (vs. intolerance) 
(OR 0.6, 95% CI=0.5-0.9) were associated with a lower probability of achieving remission 
with the second anti-TNF. Gender, age at diagnosis, smoking history, type of IBD, 
extraintestinal manifestations and duration of disease were not associated with the 
effectiveness of a second anti-TNF. 
In a subanalysis to evaluate the variables associated with short-term remission in CD 
patients who switched to a second anti-TNF, none of these factors (plus the localization and 
phenotype of the disease, the presence of perianal disease, and previous surgery owe to IBD) 
was statistically significant.  
 
Second anti-TNF: long-term effectiveness 
In the patients who achieved remission with the second anti-TNF, the median time of 
follow-up of was 19 months (IQR 8-40). After achieving remission with the second anti-TNF, 
the cumulative incidence of loss of efficacy was 45% (95% CI=41-49%): 23% at 1 year, 38% 
at 2 years, 66% at 3 years, and 62% at 5 years after switching. The proportion of patients that 
remained in remission during follow-up is shown in figure 1. The incidence of loss of efficacy 
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in patients in remission with the second anti-TNF was 19% (95% CI=17-22%) per patient-
year.  
The univariate analyses showed that combo therapy (74% combo therapy vs. 36% anti-
TNF in monotherapy, P<0.0001), and type of IBD (45% CD vs 57% UC, P=0.009) were the 
only variables associated with the loss of efficacy to a second anti-TNF (figures 2 and 3). In 
the multivariate analysis, type of IBD (UC vs. CD; HR=1.6, 95% CI=1.1-2.1, P=0.005) and 
combo therapy (HR=2.4, 95% CI=1.8-3, P<0.0001) were associated with a higher probability 
of loss of efficacy. Gender, smoking history, age at diagnosis, duration of disease, 
extraintestinal manifestations and reasons to withdraw the first anti-TNF were not associated 
with the loss of efficacy. 
In CD patients, none of these variables (plus the presence of perianal disease, the 
localization and phenotype of disease, and previous abdominal surgery owe to IBD) had 
impact on the loss of efficacy to a second anti-TNF agent.  
 
Second anti-TNF: dose-escalation 
Of the 1,122 patients who were treated with a second anti-TNF agent, 21% (230 patients) 
needed dose-escalation of the drug. Of these, 42% achieved remission. The reasons for dose-
escalation were: secondary failure (84%), partial response (14%) and non-response (2%). The 
rates of remission were, according to the reason of dose-escalation:  40% for secondary 
failure, 57% for partial response and 0% for non-responders. Only 22% of the patients who 
achieved remission with the second anti-TNF needed to increase the anti-TNF dose during 
follow-up. The median time to dose escalation was 15 months (IQR 5-37). The median 
follow-up time after dose escalation was 13 months (IQR 6-26). After escalating the anti-TNF 
dose, 70% of the patients achieved remission again. At 1 year, the vast majority of these 
patients (89%) remain in remission. 
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Second anti-TNF: safety 
Fifteen percent (95% CI=13-17%) of the patients had adverse events. Of these, 66% (95% 
CI=59-74%) required discontinuation of the drug. Therefore, 10% of all the patients treated 
with a second anti-TNF discontinued the drug because of adverse events. Infusion reactions 
and infections were the most frequent adverse events, as is shown in Table 3.   
 
Third anti-TNF 
A third anti-TNF was started in 71 patients. Of these, 45% discontinued the second anti-
TNF due to primary failure, 30% due to secondary failure, and 16% due to intolerance. In 
Table 4 are summarized the characteristics of the patients. Most of the patients (51%) 
received certolizumab as a third anti-TNF. Twenty-three percent of patients (16) had received 
combo therapy.  
 
Third anti-TNF: effectiveness 
In the short-term, 55% (95% CI=43-67%) of the patients achieved remission with the third 
anti-TNF. Of these, 16% switched to the third agent due to intolerance of the second drug, 
39% due to secondary failure and 45% due to primary failure. The median follow-up time 
after switching to a third agent was 9 months (IQR 4-16). The incidence of loss of response 
was 22% (95% CI=13-34%) per patient-year. The cumulative incidence of loss of response 
was 38% (95% CI= 23-55%): 18% at 1 year and 37% at 2 years of follow-up (Figure 4). In 
the univariate analysis, none of the variables studied were associated with the probability of 
loss of efficacy (gender, age at diagnosis, type of IBD, reasons to withdraw the second anti-
TNF, combo therapy, smoking history and extraintestinal manifestations). The multivariate 
analysis could not be performed due to de small sample size (39 patients). 
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Seven patients (11%) had adverse events. Of these, 3 patients had infection (1 herpes, 1 
bronchitis and 1 perianal abscesses), 2 patients had psoriasis, 1 paraesthesias in lower limbs, 
and 1 delayed hypersensitivity reaction. Only one patient (the patient with perianal abscesses) 




To the best of our knowledge, this is the largest cohort of IBD patients (1,122 patients) in 
whom the strategy of switching to a second anti-TNF after intolerance, primary failure, or 
secondary failure to the first one has been evaluated. Moreover, the present study is one of the 
few studies which assess the sequential administration of a third anti-TNF after failure of the 
second one.  
In IBD patients, anti-TNF agents are efficacious in inducing and maintaining disease 
remission. Nevertheless, a group of patients have no response or have a partial response to 
these agents. Furthermore, patients who initially respond may lose efficacy over time or 
develop intolerance, which sometimes leads to stopping treatment. In these possible 
scenarios, switching from one anti-TNF agent to another could represent an option13. 
In our study, 45% of the patients achieved remission with the second anti-TNF in the 
short-term. These results are in agreement with other studies2, 14-18. We also found that nearly 
half of patients diagnosed with CD achieved remission with the second anti-TNF. In CD 
patients, several studies had proven that a second anti-TNF therapy is efficacious in those 
patients who are intolerant or lose response to the prior anti-TNF drug13, 16, 18-21. However, 
only few studies with small sample sizes have analyzed the effectiveness of the strategy of the 
sequential use of a second anti-TNF if the reason for withdrawal of the first drug was primary 
failure14-16, 21-27. The rates of remission in these studies were highly variable, ranging from 
11% to 60% at one year.   
On the other hand, in UC patients, only few studies with small number of patients and 
heterogeneous designs had evaluated the effectiveness of a second anti-TNF drug, with 
reported rates of remission from 0% to 50%3, 7-9. We found that, in the short-term, UC 
patients had an overall remission rate of 41%. Moreover, the remission rate in CD patients 
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was similar to UC patients in the short-term; however, in the long-term, patients with UC had 
a higher probability of losing efficacy than CD patients. Sandborn et al. assessed the efficacy 
of ADA after IFX in 98 UC patients. At one year, the rate of remission with the second anti-
TNF was 10%. However, the reason for withdrawal the first anti-TNF withdrawal in these 
patients was not reported8. Nonetheless, in UC patients, remission rate to a second anti-TNF 
seems to be lower than remission rate in CD patients. Therefore, further studies are necessary 
in UC patients, in order to investigate the efficacy of a second anti-TNF drug in those patients 
with intolerance, primary failure or secondary failure to the first drug.  
In the present study, the probability of achieving remission at short-term was associated 
with the reason for discontinuing the first anti-TNF. In fact, patients who discontinued the 
first anti-TNF due to primary or secondary failure had a lower probability of achieving 
remission than those whose reason for switching was intolerance. According to our results, a 
very recent study evaluated the efficacy of ADA and vedolizumab in 161 UC patients who 
were previously treated with IFX. The authors reported that the efficacy of ADA was similar 
to vedolizumab in patients who were IFX intolerants. However, vedolizumab was more 
effective than ADA in IFX secondary failures28. These results are similar than those reported 
in a recent meta-analysis, in which the remission rate in the short-term was higher when the 
reason for switching was intolerance (50%) in comparison with primary (18%) or secondary 
failure (41%)2.  
According to our results, of patients who switched to a second anti-TNF due to primary 
failure to the first one, approximately 40% achieved remission. This remission rate after 
primary failure was slightly lower than in other studies14, 18, 25. This finding could be 
explained by the small sample sizes of the previous studies. Since primary failure is 
considered a class effect phenomenon, the similar structure and function shared by the anti-
TNF drugs might lead to assume that if a patient was a non-responder to the first anti-TNF 
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will not respond to the second29, 30. However, our results indicate that remission may still be 
achieved with a second anti-TNF in approximately 50% of the patients after primary non-
response to a prior drug. In according with our results, switching to another anti-TNF after 
primary failure may still be a valid therapeutic option in IBD; especially considering that the 
therapeutic armamentarium of IBD is still limited. 
We found that in patients in remission with the second anti-TNF, the incidence of loss of 
response was relatively high: 19% per patient-year, with a cumulative incidence of loss of 
response of 45% in 19 months (IQR 8-40) of follow-up. These results are similar to other 
smaller studies14, 31-33.  
In the multivariate analysis, we found that in patients who switched to a second anti-TNF, 
the long-term effectiveness was associated with the reason for switching the first drug. In fact, 
the probability of remission of the patients treated with a second anti-TNF was lower in those 
patients who switched due to primary or secondary failure to the first one, in comparison with 
those patients who switched due to intolerance. These results are consistent with a recent 
meta-analysis by our group that included 35 studies and evaluated the efficacy of a second 
anti-TNF when the previous has failed. In this study, the patients who discontinued the first 
anti-TNF due to intolerance had higher rates of remission (61%) than those who switched to a 
second anti-TNF due to primary (30%) or secondary failure (45%)2. Only one randomized 
trial has specifically evaluated the efficacy of a second-line anti-TNF agent in patients 
diagnosed with CD who were intolerant of or lost their response to a first anti-TNF drug 
(IFX) 19. In this study, ADA proved to be superior to placebo for inducing remission and 
response. The reason for discontinuing IFX (intolerance vs. secondary failure) had no impact 
in clinical improvement; however, the primary endpoint of this study was remission in week 4 
(short-term). 
Surprisingly, in patients who switched to a second anti-TNF and were on combination 
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therapy with immunomodulators, the probability of remission was lower. An explanation for 
this fact could be that patients who were on combo therapy probably had a more aggressive 
disease than those on monotherapy. In fact, we found that in patients on combo therapy the 
duration of the disease until the start of both the first and second anti-TNF was shorter than in 
patients on monotherapy, which suggests that these patients probably had a more aggressive 
disease. Nonetheless, in accordance with the results of a recent meta-analysis, combo therapy 
after starting anti-TNF therapy is no more effective than anti-TNF in monotherapy (IFX or 
ADA) in inducing or maintaining remission in patients who have been previously exposed to 
anti-TNF34. 
One-year after switching, 77% out of 45% IBD patients who achieved remission with the 
second anti-TNF maintained remission. This finding is similar to other study which included 
118 patients diagnosed with CD who switched to a second anti-TNF after failure of the 
previous anti-TNF14. Therefore, a considerable number of patients who switch to a second 
anti-TNF will be in remission in the first year; however, a high proportion of these patients 
will lose efficacy along time. Accordingly, the sequential use of a second anti-TNF is an 
option that should be considered, especially in those patients in whom the reason for 
switching was intolerance. 
In the present study, we found a higher risk of loss of efficacy in UC patients than in CD 
patients. This finding was reported by a meta-analysis which included 6 studies in UC 
patients who had primary or secondary failure to the first anti-TNF and switched to a second 
drug. The overall remission rates in these studies were lower than the reported in CD 
patients2. Nevertheless, more prospective studies are needed to investigate the effectiveness of 
a second anti-TNF agent in UC patients in whom the first drug has failed.  
In IBD patients, dose-escalation of the anti-TNF drug is a common and effective strategy 
in those patients who lose their response to anti-TNF drugs1. According to our results, 
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approximately 20% of the patients who achieved remission with the second anti-TNF 
escalated the dose due to loss of response. Of these, 70% regained remission.  This elevated 
rate of remission could be explained by the fact that all the patients escalated the dose due to 
secondary failure. Almost half of the cohort of patients who switched to a second anti-TNF 
agent and who escalated the dose of the drug achieved remission. Of these, almost two-thirds 
of the patients who escalated the dose due to partial response and half of the patients who did 
it due to secondary failure regained remission. However, none of the patients who escalated 
the dose due to non-response regained remission.  These results are similar to those of another 
study14. Our findings suggest that the escalation of the dose of the anti-TNF drug in patients 
who lose their response to a second anti-TNF may also be considered a valid therapeutic 
strategy. Moreover, according to our results, an important number of patients with partial 
response to a second anti-TNF could benefit from dose escalation of the drug. None of the 
non-responder patients who escalated the dose of the second anti-TNF achieved remission. 
Nevertheless, the number of these patients was small. For this reason, there are not enough 
data to recommend the escalation of the dose of the anti-TNF in patients who do not respond 
to the second anti-TNF.   
The sequential use of anti-TNF drugs is potentially risky since the second agent may 
worsen the immunosuppression induced by the first agent35. Of the total of patients who 
switched to a second drug, 15% had adverse events. Two-thirds of them (10% of the total 
cohort) discontinued the drug due to adverse events. In a systematic review of the use of ADA 
after IFX failure in CD patients, adverse events were reported in 13% to 69% of the patients, 
and the severity of the majority these effects were mild to moderate, with a rate of 
discontinuation ranging from 0% to 14%32. 
In clinical practice, it is not exceptional the switch to a third anti-TNF drug; however, data 
are limited. 35. In our study, we report the largest cohort of patients who switched to a third 
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anti-TNF after intolerance or failure to the second one. In the short-term, of the 71 patients 
that were included, approximately 50% achieved remission while two-thirds of them were in 
remission at 24 months. Two studies have assessed the remission rate of a third anti-TNF. 
Allez et al. studied 67 patients diagnosed with CD that were treated with a third anti-TNF due 
to intolerance or failure to the second drug. In week six, 61% of the patients had clinical 
response while 51% of the patients had clinical response at week 20.36. Silva et al. studied 63 
IBD patients who received a third anti-TNF after intolerance or loss of response. Remission 
was achieved in 36% of these patients, and over 50% of the patients who achieved remission 
remained on the third anti-TNF after one year37 In our study, the probability of maintaining 
remission after the third anti-TNF was higher than Silva et. al. study. However, the long-term 
benefit of a third anti-TNF agent is still unknown. 
We found that 11% of patients had adverse events, although only in one of them the drug 
had to be withdrawn. However, the use of a third anti-TNF raises additional safety concerns. 
Allez et al. reported that 14 patients had to discontinue the third anti-TNF due to severe 
adverse events. Also, two deaths were reported by the authors36. Nonetheless, there were no 
deaths reported in the study of Silva et. al. during the follow-up period37. Although the 
efficacy of switching to a third anti-TNF seems to be relatively favorable, this strategy cannot 
be generally recommended because of the risk of severe adverse events. Especially because 
there are available for the treatment of IBD other recently approved medical options (e.g. 
vedolizumab, ustekinumab) that are effective and safe. 
The present study has several limitations. First, information about anti-TNF trough levels, 
anti-drug antibodies and endoscopic activity was not available. Nonetheless, due to the fact 
that this is a retrospective study the investigators made an effort in order to obtain information 
on all components of clinical indices. Second, since this was a real-life study, the treating 
physicians decided to discontinue one anti-TNF and switch to another based on their criteria. 
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Third, the number of patients who switched to a third anti-TNF was small, and the follow-up 
period of these patients was relatively short. However, the number of patients in which this 
strategy was evaluated is one of the largest that has been published.  
One of the main strengths of this study is that it reflects real-life clinical practice. 
Moreover, this is the largest cohort of IBD patients in whom the strategy of switching to a 
second anti-TNF after intolerance, primary failure or secondary failure to the first one has 
been evaluated. In addition, this is the largest study in which the strategy of the sequential use 
of a third anti-TNF has been evaluated. 
In conclusion, our results suggest that the sequential use of a second anti-TNF is 
efficacious in IBD patients after intolerance, primary failure or secondary failure to a first 
anti-TNF. In any case, a high proportion of the patients who achieve remission with a second 
anti-TNF lose response afterward. Combination therapy with immunomodulators and type of 
IBD are predictors of loss of response to a second anti-TNF. Of the patients treated with a 
third anti-TNF, two-thirds achieved remission with the drug; nonetheless, a significant 
number of these patients experienced loss of efficacy over time. Finally, the sequential use of 
a second anti-TNF is safe; although switching to a third anti-TNF seems to be relatively safe, 
this last strategy cannot be generally recommended in clinical practice. 
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Table 1. Baseline characteristics of the patients. 
 
Variables Total 
Type of disease, n (%) 
  Crohn’s disease 




Male, n (%) 563 (50.2) 
Mean age at diagnosis, years (range) 30 (5-79) 
Median time from diagnosis to the start of the 
anti-TNF therapy, months (IQR) 
  First anti-TNF 
  Second anti-TNF 






Extra-intestinal manifestations, n (%) 417 (37.2) 
Smoking history, n (%) 383 (34.1) 
History of abdominal surgery, n (%) 341 (56.9) 
Type of first anti-TNF therapy, n (%) 
  Infliximab 
  Adalimumab 
  Certolizumab 






Type of second anti-TNF therapy, n (%) 
  Infliximab 
  Adalimumab  
  Certolizumab 






Type of third anti-TNF therapy, n (%) 
  Infliximab 
  Adalimumab  
  Certolizumab 






Concomitant IMMs, n (%) 
  First anti-TNF 
  Second anti-TNF 





Reasons for the first anti-TNF discontinuation, 
n (%) 
  Non-response  
  Partial response 
  Loss of efficacy 







Montreal location at Crohn’s disease diagnosis, 
n (%) 
  L1 (ileal) 
  L2 (colonic) 
  L3 (ileocolonic) 








Montreal behavior at Crohn’s disease 
diagnosis, n (%) 
  B1 (inflammatory) 
  B2 (stricturing) 






Perianal disease, n (%) 358 (43.7) 
Ulcerative colitis extension, n (%)  
  Proctitis 
  Left side colitis 
  Extensive colitis 



























Table 2. Multivariate analysis of factors associated with the probability of achieving 
remission with the second anti-TNF. 
 
Factors OR 95% CI P-value 
Concomitant IMMs  0.5 0.4-0.7 <0.0001 
To withdraw the first anti-TNF 
due to a primary failure (vs. 
intolerance) 
0.6 0.4-0.9 0.007 
To withdraw the first anti-TNF 
due to secondary failure (vs. 
intolerance) 
0.6 0.5-0.9 0.003 
Gender 0.84 0.7-1.1 0.1 
Age at diagnosis 0.9 0.9-1 0.1 
Smoking history 1.1 0.9-1.5 0.4 
Type of IBD (UC vs. CD) 0.9 0.7-1.3 0.5 
Extraintestinal manifestations 0.9 0.7-1.2 0.5 
Duration of disease  1 0.99-1.001 0.9 
OR: odds ratio; IMMs: immunomodulators; CI: confidence interval; IBD: inflammatory 














Table 3. Adverse events with the second anti-TNF drug 
 
Adverse event N (%) 
Infusion reaction  45 (26.4) 
Infections 45 (26.4) 
Delayed hypersensitivity  reaction 26 (15.3) 
Toxicodermia 17 (10) 
Drug-induced psoriasis 15 (8.8) 
Drug-induced lupus 8 (4.7) 
Headache 5 (3) 
Malignancy 4 (2.4) 
Thrombocytopenia 3 (1.8) 
Anaphylaxis  1 (0.6) 





Table 4. Baseline characteristics of the patients who switched to a third anti-TNF. 
 
Variables Total 






Male, n (%) 39(54.9) 
Mean age at diagnosis, years (range) 32 (11-75) 
Extra-intestinal manifestations, n (%) 29 (40.8) 
Smoking history, n (%) 22 (34.9) 
History of abdominal surgery, n (%) 20 (28.2) 
Reasons for the second anti-TNF 
discontinuation, n (%) 
-Primary failure  
-Secondary failure 
















Montreal behaviour at Crohn’s disease 









Perianal disease, n (%) 19 (42.2) 
Ulcerative colitis extension, n (%)  
-Proctitis 
-Left side colitis 










Figure 1. Kaplan-Meier curve of long-term remission after treatment with a second anti-TNF. 
Figure 2. Kaplan-Meier analysis of long-term remission after treatment with a second anti-
TNF in Crohn’s disease vs. ulcerative colitis patients. 
Figure 3. Kaplan-Meier analysis of long-term remission after treatment with a second anti-
TNF in patients treated with immunomodulators vs. untreated patients. 
Figure 4. Kaplan-Meier curve of long-term remission after treatment with a third anti-TNF. 
Figure 5. Flow chart of the patients who switched to a second and a third anti-TNF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
